Revolution Medicines Initiates Phase 3 Trial for Zoldonrasib in First-Line Metastatic Pancreatic Cancer
RVMD has more than doubled off its 52-week low of $34.
Summary
Revolution Medicines has initiated patient treatment in its Phase 3 RASolute 305 clinical trial for zoldonrasib, evaluating it in combination with chemotherapy as a first-line treatment for RAS G12D metastatic pancreatic cancer. This marks a significant advancement for the company's pipeline, building on the positive late-stage results for its other RAS(ON) inhibitor, daraxonrasib, in pancreatic cancer earlier this year, which was followed by a $2 billion capital raise. Advancing zoldonrasib into a pivotal trial for a high unmet need indication like first-line pancreatic cancer, where RAS G12D is a prevalent mutation, adds substantial long-term value and de-risks the company's oncology portfolio.
At the time of this announcement, RVMD was trading at $162.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $35.3B. The 52-week trading range was $34.00 to $166.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.